cryptogon.com

Introduction: Autism spectrum disorder (ASD) is now estimated to affect more than 1 in 31 children in the United States, with prevalence rising sharply over the past two decades and posing an increasing burden to families and public health systems. Most of the literature on ASD characterizes it as a complex neurodevelopmental condition shaped by multiple determinants, including genetic liability, immune dysregulation, perinatal stressors, and environmental toxicants. Since 1996, the possible role of childhood vaccination has also been discussed and debated. This review synthesizes the full range of evidence to clarify both vaccine-related and non-vaccine contributors to ASD risk.

Methods: We comprehensively examined epidemiologic, clinical, and mechanistic studies evaluating potential ASD risk factors, assessing outcomes, exposure quantification, strength and independence of associations, temporal relationships, internal and external validity, overall cohesiveness, and biological plausibility.

Results: We found potential determinants of new onset ASD before the age of 9 years old to include: older parents (>35 years mother, >40 years father), premature delivery before 37 weeks of gestation, common genetic variants, siblings with autism, maternal immune activation, in utero drug exposure, environmental toxicants, gut-brain axis alterations and combination routine childhood vaccination. These diverse genetic, environmental, and iatrogenic factors appear to intersect through shared pathways of immune dysregulation, mitochondrial dysfunction, and neuroinflammation, culminating in neurodevelopmental injury and regression in susceptible children. Of 136 studies examining childhood vaccines or their excipients, 29 found neutral risks or no association, while 107 inferred a possible link between immunization or vaccine components and ASD or other neurodevelopmental disorders (NDDs), based on findings spanning epidemiologic, clinical, mechanistic, neuropathologic, and case-report evidence of developmental regression. 12 studies comparing routinely immunized versus completely unvaccinated children or young adults consistently demonstrated superior overall health outcomes among the unvaccinated, including significantly lower risks of chronic medical problems and neuropsychiatric disorders such as ASD. The neutral association papers were undermined by absence of a genuinely unvaccinated control group—with partial or unverified immunization even among those classified as unvaccinated—alongside registry misclassification, ecological confounding, and averaged estimates that obscure effects within vulnerable subgroups. Only a few case–control studies verified vaccination through medical records or parent-held cards, and none performed independent clinical assessments of the children for ASD. In contrast, the positive association studies found both population signals (ecologic, cohort, case–control, dose–response, and temporal clustering) and mechanistic findings converging on biologic plausibility: antigen, preservative, and adjuvant (ethyl mercury and aluminum) induced mitochondrial and neuroimmune dysfunction, central nervous system injury, and resultant incipient phenotypic expression of ASD. Clustered vaccine dosing and earlier timing of exposure during critical neurodevelopmental windows appeared to increase the risk of ASD. These findings parallel strong, consistent increases in cumulative vaccine exposure during early childhood and the reported prevalence of autism across successive birth cohorts. To date, no study has evaluated the safety of the entire cumulative pediatric vaccine schedule for neurodevelopmental outcomes through age 9 or 18 years. Nearly all existing research has focused on a narrow subset of individual vaccines or components—primarily MMR, thimerosal-containing, or aluminum-adjuvanted products—meaning that only a small fraction of total childhood vaccine exposure has ever been assessed for associations with ASD or other NDDs.

“What resilience means to us is that we have power, no matter what, 24/7,” Dr. Jeff Waksman, Principal Deputy Assistant Secretary of the Army for Installations, Energy and Environment, said during a media roundtable attended by TWZ at last week’s Association of the U.S. Army’s (AUSA) main annual conference.

With the government shutdown now well into its 25th day, Senate Republicans and Democrats remain at an impasse over expiring health care subsidies.

“Bottom line, the well has run dry,” the USDA wrote on its website. “At this time, there will be no benefits issued November 01.”

During fiscal year 2024, the government’s Supplemental Nutrition Assistance Program (SNAP) supported, on average, 41.7 million participants, or 12.3 percent of the U.S. population, every month. Anywhere between 4.8 percent and 21.2 percent of each state’s population was on SNAP in 2024.

But Mellon’s donation works out to only about $100 per service member. It costs nearly $6.4 billion to pay U.S. troops every two weeks.

And using his money might run afoul of federal law, according to the Times, which cited two people familiar with the matter in identifying the billionaire railroad magnate as the donor.

When President Donald Trump announced the donation at the White House on Thursday, he did not identify the man by name, but described him as a “great patriot” and a “friend of mine.”

Donald Trump Jr joined the company as an adviser in 2024. According to a report in Financial Times, Trump Jr holds a $4 million stake in the company. He hold a total of 331,580 shares of the company, it had declared when Trump Jr joined the organisation.

The Army has signaled that it would also purchase an additional 20,000 parts from Unusual Machines next year.

Allan Evans, the company’s CEO, said he believes this is Unusual Machines’ largest-ever order from the US government. When asked if Donald Trump Jr helped the company with the deal, Allan Evans said that he did not.

Trump Jr’s spokesperson told FT: “Don has never communicated with anyone in the Administration on behalf of Unusual Machines or about the contract in question. His advisory role with them has nothing to do with interfacing with the government.”